All In Biotech

Drug Trial Radar · NCT04479917

Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction

A Multi-Center ,Randomized, Double-Blind, Placebo-Controlled, Dose-Exploring Study to Evaluate the Efficacy and Safety of TPN171H in China Male Patients With Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Jul 23, 2020

Primary completion

Jul 26, 2021

Study completion Jul 26, 2021

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
Collaborators
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
First posted
Jul 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an exploratory clinical study to presume the optimum usage and dosage for a therapeutic confirmatory study by evaluating the efficacy and safety of TPN171H 5mg, 10mg, 20mg or placebo administered orally in patients with erectile dysfunction. In conclusions, Patients with erectile dysfunction (ED) were administered placebo, TPN171H 5mg, 10mg or 20mg 30 minutes to 4 hours before sexual intercourse for 8 weeks.

Conditions

  • Erectile Dysfunction

Interventions

  • TPN171HDrug

    Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period

  • placeboDrug

    Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the International Index of Erectile Function - Erectile Function Domain (IIEF-EF) at Week 8Time frame: baseline and 8 weeks
  2. Change From Baseline in Question 2 of the Patient Sexual Encounter Profile (SEP) Diary at Week 8 in Percentage of Yes ResponsesTime frame: baseline and 8 weeks
  3. Change From Baseline in Question 3 of the Patient Sexual Encounter Profile (SEP) Diary at Week 8 in Percentage of Yes ResponsesTime frame: baseline and 8 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Second Affiliated Hospital of Suzhou University

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University

    Changchun, Jinlin, China

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.